You are Trying to View a Free Article

Daily News You Can't Find Anywhere Else

WuXi Biologics Authorizes Exelixis to Expand Oncology Biological Drug Production, an Industrial Info Market Brief

default

Industry Segment: Market Brief | Word Count: 72 Words
Attachment: A

WuXi Biologics has authorized Exelixis exclusively to expand its oncology biological drug production. WuXi AppTec, which includes WuXi Biologics, has 14 plants, with half in the U.S. and half in China.

WuXi AppTec has invested more than $707.4 million in China to construct or upgrade four plants since 2020.

Subscribe Now! All Fields Required...

Standard Membership - Free